ADVANCEMENT OF POTENT BROAD SPECTRUM ENTEROVIRUS THERAPEUTICS

有效的广谱肠道病毒治疗的进展

• 批准号: 10684969
• 负责人: INGRID PERSSON
• 金额: $ 149.92万
• 依托单位: INTEGRATED RESEARCH ASSOCIATES, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10684969
• 关键词: Child; Contracts; Enterovirus; Enterovirus 68; Enterovirus 71; Family; Family Picornaviridae; Hand, Foot and Mouth Disease; Monoclonal Antibodies; National Institute of Allergy and Infectious Disease; Phase; Small Business Innovation Research Grant; Therapeutic; Vaccines; Virus; acute flaccid myelitis; member; nervous system disorder; pandemic disease; priority pathogen; therapeutic development

This is a phase II SBIR Contract to develop broad spectrum monoclonal antibodies against enteroviruses. Enteroviruses cause neurological diseases mainly in young children including acute flaccid myelitis (AFM) and Hand Foot and Mouth Disease (HFMD). There is no therapeutics against these viruses or vaccines against them approved in the US. These viruses are members of picornavirus family, a priority pathogen of NIAID because of their high pandemic potential.

这是一项第二阶段的SBIR合同，旨在开发针对肠道病毒的广谱单抗。肠道病毒引起的神经系统疾病主要发生在幼儿身上，包括急性弛缓性脊髓炎(AFM)和手足口病(HFMD)。美国目前还没有针对这些病毒的疗法或疫苗。这些病毒是微小核糖核酸病毒家族的成员，该家族是NIAID的优先病原体，因为它们具有很高的大流行潜力。